Deglycosylation and subcellular redistribution of VMAT2 in the mesostriatal system during normal aging.

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Neurobiology of Aging

• Publication date

  2008-11-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/J.NEUROBIOLAGING.2007.04.003PMID 17582657
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Positron Emission Tomography of Monoaminergic Vesicular Binding in Aging and Parkinson Disease

  2006cited by this paper
• Age-Related Decline in Striatal Dopamine TransporterBindingwith Iodine-123-$-CITSPECT

  2006cited by this paper
• Variants of the primate vesicular monoamine transporter-2.

  2005cited by this paper
• Bupropion increases striatal vesicular monoamine transport.

  2005cited by this paper
• Age-Dependent Methamphetamine-Induced Alterations in Vesicular Monoamine Transporter-2 Function: Implications for Neurotoxicity

  2005cited by this paper
• Comparison of the subregional distributions of the monoamine vesicular transporter and dopamine uptake complex in the rat striatum and changes during aging

  2005cited by this paper
• Role of monoamine transporters in mediating psychostimulant effects

  2005cited by this paper
• N-glycosylation is essential for vesicular targeting of synaptotagmin 1.

  2004cited by this paper
• N-Glycosylation Is Crucial for Folding, Trafficking, and Stability of Human Tripeptidyl-peptidase I*

  2004cited by this paper
• Alterations in Vesicular Dopamine Uptake Contribute to Tolerance to the Neurotoxic Effects of Methamphetamine

  2004cited by this paper
• Glycosylation Affects the Protein Stability and Cell Surface Expression of Kv1.4 but Not Kv1.1 Potassium Channels

  2004cited by this paper
• The role of mitochondrial oxidative stress in aging.

  2003cited by this paper
• Decreased plasma membrane expression of striatal dopamine transporter in aging.

  2003cited by this paper
• Marked disparity between age‐related changes in dopamine and other presynaptic dopaminergic markers in human striatum

  2003cited by this paper
• Decreased limbic vesicular monoamine transporter 2 in a genetic rat model of depression.

  2003cited by this paper
• Loss of striatal vesicular monoamine transporter protein (VMAT2) in human cocaine users.

  2003cited by this paper
• GM1 enhances dopaminergic markers in the brain of aged rats.

  2003cited by this paper
• Ageing and the nigrostriatal dopaminergic system

  2002cited by this paper
• Age‐related changes in the striatal dopaminergic system in the living brain: A multiparametric PET study in conscious monkeys

  2002cited by this paper
• Processing of gene expression data generated by quantitative real-time RT-PCR.

  2002cited by this paper
• Differential trafficking of the vesicular monoamine transporter-2 by methamphetamine and cocaine.

  2002cited by this paper
• Changes in somatodendritic but not terminal dopamine
regulation in aged rhesus monkeys

  2002cited by this paper
• Methylphenidate Redistributes Vesicular Monoamine Transporter-2: Role of Dopamine Receptors

  2002cited by this paper
• SNP market view: opportunities, technologies, and products.

  2002cited by this paper
• Intracellular functions of N-linked glycans.

  2001cited by this paper
• Dopamine D1 Receptor-Dependent Trafficking of Striatal NMDA Glutamate Receptors to the Postsynaptic Membrane

  2001cited by this paper
• Changes in Vesicular Monoamine Transporter (VMAT2) and Synaptophysin in Rat Substantia nigra and Prefrontal Cortex Induced by Psychotropic Drugs

  2001cited by this paper
• Effect of novel stressors on gene expression of tyrosine hydroxylase and monoamine transporters in brainstem noradrenergic neurons of long-term repeatedly immobilized rats.

  2001cited by this paper
• Reserpine or chronic paroxetine treatments do not modify the vesicular monoamine transporter 2 expression in serotonin-containing regions of the rat brain.

  2000cited by this paper
• Analysis of VMAT2 Binding After Methamphetamine or MPTP Treatment

  2000cited by this paper
• Age‐changes of brain synapses and synaptic plasticity in response to an enriched environment

  1999cited by this paper
• Selective changes in the contents of noradrenaline, dopamine and serotonin in rat brain areas during aging

  1999cited by this paper
• Multiple antioxidants in the prevention and treatment of Parkinson's disease.

  1999cited by this paper
• Age-related changes in the capacity, rate, and modulation of dopamine uptake within the striatum and nucleus accumbens of Fischer 344 rats: an in vivo electrochemical study.

  1999cited by this paper
• Increased MPTP Neurotoxicity in Vesicular Monoamine Transporter 2 Heterozygote Knockout Mice

  1998cited by this paper
• The neurotoxin 1-methyl-4-phenylpyridinium is sequestered within neurons that contain the vesicular monoamine transporter.

  1998cited by this paper
• Age-related changes in D2 receptor binding with iodine-123-iodobenzofuran SPECT.

  1998cited by this paper
• Understanding cell death in parkinson's disease

  1998cited by this paper
• Sensitivity to ageing of the limbic dopaminergic system: a review.

  1998cited by this paper
• VMAT2 knockout mice: heterozygotes display reduced amphetamine-conditioned reward, enhanced amphetamine locomotion, and enhanced MPTP toxicity.

  1997cited by this paper
• Knockout of the vesicular monoamine transporter 2 gene results in neonatal death and supersensitivity to cocaine and amphetamine.

  1997cited by this paper
• Age‐related and regional differences in dopamine transporter mRNA expression in human midbrain

  1997cited by this paper
• The Vesicular Monoamine Transporter, in Contrast to the Dopamine Transporter, Is Not Altered by Chronic Cocaine Self-Administration in the Rat

  1996cited by this paper
• Presynaptic monoaminergic vesicles in Parkinson's disease and normal aging

  1996cited by this paper
• Age-related decline in striatal dopamine transporter binding with iodine-123-beta-CITSPECT.

  1995cited by this paper
• Differential expression of two vesicular monoamine transporters

  1995cited by this paper
• The vesicular monoamine transporter is not regulated by dopaminergic drug treatments.

  1995cited by this paper
• Aging-related changes in rat striatal D2 receptor mRNA-containing neurons: a quantitative nonradioactive in situ hybridization study

  1995cited by this paper
• Dopamine D2, D3, and D4 receptor mRNA levels in rat brain and pituitary during aging.

  1994cited by this paper
• Biochemistry and molecular biology of the vesicular monoamine transporter from chromaffin granules.

  1994cited by this paper
• Expression and regulation of the bovine vesicular monoamine transporter gene

  1993cited by this paper
• Decreased tyrosine hydroxylase mRNA but not cholecystokinin mRNA in the pars compacta of the substantia nigra and ventral tegmental area of aged rats.

  1993cited by this paper
• Dopamine transporter mRNA content in human substantia nigra decreases precipitously with age.

  1992cited by this paper
• A cDNA that suppresses MPP+ toxicity encodes a vesicular amine transporter.

  1992cited by this paper
• Aging Produces a Specific Pattern of Striatal Dopamine Loss: Implications for the Etiology of Idiopathic Parkinson's Disease

  1992cited by this paper
• Expression cloning of a reserpine-sensitive vesicular monoamine transporter.

  1992cited by this paper
• Age-related decline in rat striatal dopamine metabolism is regionally homogeneous.

  1990cited by this paper
• Striatal dopamine deficiency in parkinson's disease: Role of aging

  1989cited by this paper
• Age-correlated loss of dopamine uptake sites labeled with [3H]GBR-12935 in human putamen.

  1989cited by this paper
• Differential decrease in the rate of dopamine synthesis in several dopaminergic neurons of aged rat brain.

  1987cited by this paper
• Human brain dopamine receptors in children and aging adults

  1987cited by this paper
• Divergent changes in D-1 and D-2 dopamine binding sites in human brain during aging.

  1987cited by this paper
• Brain catecholamine content and turnover in aging rats.

  1985cited by this paper
• Synapsin I (protein I), a nerve terminal-specific phosphoprotein. III. Its association with synaptic vesicles studied in a highly purified synaptic vesicle preparation

  1983cited by this paper
• The Rat Brain in Stereotaxic Coordinates

  1983cited by this paper
• DYNAMIC RESPONSE OF CHEST WALL AND LUNG INJURIES IN RABBITS EXPOSED TO AIR SHOCK WAVES OF SHORT DURATION.

  1964cited by this paper
• EVIDENCE FOR THE EXISTENCE OF MONOAMINE-CONTAINING NEURONS IN THE CENTRAL NERVOUS SYSTEM. I. DEMONSTRATION OF MONOAMINES IN THE CELL BODIES OF BRAIN STEM NEURONS.

  1964cited by this paper

• Neuromelanin and selective neuronal vulnerability to Parkinson's disease.

  2025cites this paper
• An amphipol‐stabilized multi‐pass transmembrane protein as an immunogen to generate mouse memory B cells against native VMAT2

  2025cites this paper
• Amphetamine Exposure during Embryogenesis Alters Expression and Function of Tyrosine Hydroxylase and the Vesicular Monoamine Transporter in Adult C. elegans

  2024cites this paper
• The neurobiological effects of senescence on dopaminergic system: a comprehensive review.

  2024cites this paper
• Oxidative stress induced by sustained supraphysiological intrastriatal GDNF delivery is prevented by dose regulation

  2023cites this paper
• Neurobiological and Pharmacological Perspectives of D3 Receptors in Parkinson’s Disease

  2022cites this paper
• Long-term exposure to GDNF induces dephosphorylation of Ret, AKT, and ERK1/2, and is ineffective at protecting midbrain dopaminergic neurons in cellular models of Parkinson's disease.

  2021cites this paper
• Strain- and age-dependent features of the nigro-striatal circuit in three common laboratory mouse strains, C57BL/6J, A/J, and DBA/2J - Implications for Parkinson’s disease modeling

  2020cites this paper
• Glycosylation States of Pre- and Post-synaptic Markers of 5-HT Neurons Differ With Sex and 5-HTTLPR Genotype in Cortical Autopsy Samples

  2018cites this paper
• MECHANISMS OF VESICULAR MONOAMINE TRANSPORTER-2 DEGRADATION

  2017cites this paper
• Genetic Variation in the Vesicular Monoamine Transporter: Preliminary Associations With Cognitive Outcomes After Severe Traumatic Brain Injury

  2017cites this paper
• Immunochemical localization of vesicular monoamine transporter 2 (VMAT2) in mouse brain.

  2017cites this paper
• Glycosylation of solute carriers: mechanisms and functional consequences

  2016cites this paper
• Deficits in coordinated motor behavior and in nigrostriatal dopaminergic system ameliorated and VMAT2 expression up-regulated in aged male rats by administration of testosterone propionate.

  2016cites this paper
• Ageing of the somatic motor nervous system: a nuclear and mitochondrial genome perspective

  2016cites this paper
• ge-related gene expression changes in substantia nigra dopamine eurons of the rat

  2015cites this paper
• The degeneration of dopaminergic synapses in Parkinson's disease: A selective animal model.

  2015cites this paper
• The Role of E3 Ligase Parkin in Trafficking of Monoamine Storage Vesicles in Rat Model of Methamphetamine Neurotoxicity

  2015cites this paper
• Modulation of the expression and function of dopaminergic presynaptic proteins by the statins : Potential implication for the therapeutic intervention in Parkinson’s disease.

  2015cites this paper
• Parkinson's disease as a result of aging

  2015cites this paper
• Reduced vesicular storage of catecholamines causes progressive degeneration in the locus ceruleus.

  2014cites this paper
• Coordinated expression of dopamine transporter and vesicular monoamine transporter in the primate striatum during development

  2013cites this paper
• Effects of brain‐derived neurotrophic factor on dopaminergic function and motor behavior during aging

  2011cites this paper
• Influence of aging on the dopaminergic neurons in the substantia nigra pars compacta of rats.

  2011cites this paper
• Biphasic dopamine regulation in mesoaccumbens pathway in response to non-contingent binge and escalating methamphetamine regimens in the Wistar rat

  2011cites this paper
• Distribution of Vesicular Monoamine Transporter 2 Protein in Human Brain: Implications for Brain Imaging Studies

  2011influential citation
• Cleavage of the vesicular glutamate transporters under excitotoxic conditions.

  2011cites this paper
• Protective effect of Zhen-Wu-Tang (ZWT) through keeping DA stable and VMAT 2/DAT mRNA in balance in rats with striatal lesions induced by MPTP.

  2011cites this paper
• Effect of low endogenous brain-derived neurotrophic factor levels on striatal dopamine dynamics

  2011cites this paper
• Vulnerability of Mesostriatal Dopaminergic Neurons in Parkinson's Disease

  2010cites this paper
• 7 Vesicular Neurotransmitter Transporters

  2009cites this paper
• Increased expression of VMAT2 in dopaminergic neurons during nicotine withdrawal.

  2009cites this paper
• Genetic and Epigenetic SLC18A2 Silencing in Prostate Cancer Is an Independent Adverse Predictor of Biochemical Recurrence after Radical Prostatectomy

  2009cites this paper
• Trafficking of Vesicular Neurotransmitter Transporters

  2008influential citation